دورية أكاديمية
أعرض في EDS

Challenges and advances in the medical treatment of granulomatous amebic encephalitis.

التفاصيل البيبلوغرافية
العنوان: Challenges and advances in the medical treatment of granulomatous amebic encephalitis.
المؤلفون: Spottiswoode N; Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA., Haston JC; Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Hanners NW; Division of Pediatric Infectious Diseases, University of Texas Southwestern, Dallas, TX, USA., Gruenberg K; Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, CA, USA., Kim A; Department of Clinical Pharmacy, Zuckerberg San Francisco General, San Francisco, CA, USA., DeRisi JL; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.; Chan Zuckerberg Biohub SF, San Francisco, CA, USA., Wilson MR; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA.
المصدر: Therapeutic advances in infectious disease [Ther Adv Infect Dis] 2024 Feb 02; Vol. 11, pp. 20499361241228340. Date of Electronic Publication: 2024 Feb 02 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 101606715 Publication Model: eCollection Cited Medium: Print ISSN: 2049-9361 (Print) Linking ISSN: 20499361 NLM ISO Abbreviation: Ther Adv Infect Dis Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : SAGE Publications, [2013]-
مستخلص: Granulomatous amebic encephalitis, caused by the free-living amebae Balamuthia mandrillaris or Acanthamoeba species, is a rare and deadly infectious syndrome with a current mortality rate of >90%. Much work remains to define the optimal treatment for these infections. Here, we provide a comprehensive overview of the supporting evidence behind antimicrobials currently recommended by the Centers for Disease Control and Prevention (CDC) with updated statistics on survival rates and medication usage from the CDC Free-Living Ameba Database. We also discuss promising treatments, especially the emerging therapeutic agent nitroxoline, and provide recommendations for the next steps in this area.
Competing Interests: The authors declare that there is no conflict of interest.
(© The Author(s), 2024.)
References: Curr Infect Dis Rep. 2012 Aug;14(4):391-6. (PMID: 22729402)
Am J Transplant. 2014 Jun;14(6):1417-24. (PMID: 24840013)
Emerg Microbes Infect. 2020 Dec;9(1):2348-2357. (PMID: 33048025)
Arch Med Res. 2006 Aug;37(6):723-9. (PMID: 16824931)
Antimicrob Agents Chemother. 2020 Apr 21;64(5):. (PMID: 32071043)
PLoS Negl Trop Dis. 2020 Sep 24;14(9):e0008353. (PMID: 32970675)
Curr Opin Infect Dis. 2023 Jun 1;36(3):186-191. (PMID: 37093056)
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:80-94. (PMID: 31707263)
J Eukaryot Microbiol. 1993 Jul-Aug;40(4):504-14. (PMID: 8330028)
Antimicrob Agents Chemother. 2002 Mar;46(3):695-701. (PMID: 11850250)
Clin Infect Dis. 2016 Oct 1;63(7):878-888. (PMID: 27358357)
J Eukaryot Microbiol. 2003;50 Suppl:508-9. (PMID: 14736144)
Parasitol Res. 2017 Apr;116(4):1339-1344. (PMID: 28251314)
Parasitol Res. 2007 Mar;100(4):775-82. (PMID: 17111178)
J Vet Diagn Invest. 2023 May;35(3):311-316. (PMID: 36908206)
J Neuropathol Exp Neurol. 1996 Jul;55(7):815-21. (PMID: 8965096)
Clin Microbiol Rev. 2014 Jan;27(1):68-88. (PMID: 24396137)
Transpl Infect Dis. 2017 Apr;19(2):. (PMID: 28067969)
J Pediatric Infect Dis Soc. 2022 Dec 28;11(12):578-581. (PMID: 36041049)
MMWR Morb Mortal Wkly Rep. 2013 Aug 23;62(33):666. (PMID: 23965830)
Clin Infect Dis. 2019 May 17;68(11):1815-1822. (PMID: 30239654)
Pathogens. 2020 Jun 16;9(6):. (PMID: 32560115)
mBio. 2018 Oct 30;9(5):. (PMID: 30377287)
Lancet. 1972 Dec 23;2(7791):1343-5. (PMID: 4118209)
Antimicrob Agents Chemother. 2020 Apr 21;64(5):. (PMID: 32094126)
Emerg Infect Dis. 2023 Jan;29(1):197-201. (PMID: 36573629)
Parasitol Res. 2011 Mar;108(3):621-7. (PMID: 20978791)
J Clin Microbiol. 2005 Feb;43(2):629-34. (PMID: 15695656)
Mycoses. 2020 Oct;63(10):1047-1059. (PMID: 32772402)
J Infect Dis. 1988 May;157(5):985-9. (PMID: 3258901)
J Clin Microbiol. 2015 Sep;53(9):3072-6. (PMID: 26135864)
Antimicrob Agents Chemother. 1996 Mar;40(3):825-6. (PMID: 8851625)
Cornea. 1997 Jan;16(1):94-100. (PMID: 8985640)
Antimicrob Agents Chemother. 2019 Dec 20;64(1):. (PMID: 31685474)
Clin Infect Dis. 2010 Jul 15;51(2):e7-11. (PMID: 20550438)
Antimicrob Agents Chemother. 2015 Aug;59(8):4707-13. (PMID: 26014948)
JMM Case Rep. 2016 Jun 28;3(3):e005031. (PMID: 28348755)
Vet Pathol. 2004 Sep;41(5):506-10. (PMID: 15347823)
Trans R Soc Trop Med Hyg. 1991 Sep-Oct;85(5):608-11. (PMID: 1780988)
J Eukaryot Microbiol. 1993 Jan-Feb;40(1):14-7. (PMID: 8457798)
Ther Drug Monit. 1992 Jun;14(3):255-60. (PMID: 1412612)
Case Rep Oncol. 2021 Feb 15;14(1):24-28. (PMID: 33776678)
Ann Neurol. 2015 Nov;78(5):722-30. (PMID: 26290222)
Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):873-8. (PMID: 3309832)
BMC Infect Dis. 2014 Nov 27;14:628. (PMID: 25427651)
Clin Infect Dis. 1997 May;24(5):854-9. (PMID: 9142782)
Open Forum Infect Dis. 2023 Jan 12;10(1):ofac682. (PMID: 36655187)
Pharmaceuticals (Basel). 2021 Dec 11;14(12):. (PMID: 34959694)
J Parasitol. 2011 Jun;97(3):538-40. (PMID: 21506779)
Med Mycol. 2021 Sep 03;59(9):939-942. (PMID: 34143187)
Microbiology (Reading). 2004 Sep;150(Pt 9):2837-2842. (PMID: 15347743)
J Eukaryot Microbiol. 2006 Mar-Apr;53(2):121-6. (PMID: 16579814)
Exp Parasitol. 2019 Jun;201:90-92. (PMID: 31059693)
J Clin Microbiol. 1996 Feb;34(2):385-8. (PMID: 8789020)
Clin Microbiol Rev. 2010 Oct;23(4):858-83. (PMID: 20930076)
Clin Infect Dis. 2021 Jul 1;73(1):e19-e27. (PMID: 32369575)
Antimicrob Agents Chemother. 1974 Sep;6(3):282-9. (PMID: 15830474)
Primates. 2021 Jan;62(1):51-61. (PMID: 32920664)
Clin Infect Dis. 2003 Nov 15;37(10):1304-12. (PMID: 14583863)
J Antimicrob Chemother. 2023 Apr 3;78(4):1015-1022. (PMID: 36857467)
J Eukaryot Microbiol. 2013 Sep-Oct;60(5):539-43. (PMID: 23869955)
Sci Rep. 2021 Nov 4;11(1):21664. (PMID: 34737367)
Clin Infect Dis. 2008 Aug 1;47(3):303-27. (PMID: 18582201)
معلومات مُعتمدة: T32 AI007641 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Acanthamoeba; Balamuthia; ameba; drug repurposing; encephalitis
تواريخ الأحداث: Date Created: 20240205 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10838035
DOI: 10.1177/20499361241228340
PMID: 38312848
قاعدة البيانات: MEDLINE
الوصف
تدمد:2049-9361
DOI:10.1177/20499361241228340